Development and Validation of an Integrated Metabolism‐Obesity Index for Screening Renal Impairment in Patients With Newly Diagnosed Type 2 Diabetes Mellitus
Open Access
- 1 January 2026
- journal article
- research article
- Published by Wiley in Journal of Diabetes Research
- Vol. 2026 (1) , e5164386
Abstract
Background: Diabetic kidney disease, a severe diabetes microvascular complication affecting 30%~40% of diabetic patients, raises end‐stage renal disease and mortality risks. This study is aimed at developing and validate a novel index combining obesity measures and metabolic parameters to screen renal impairment in newly diagnosed T2DM patients. Methods: A total of 387 and 259 newly diagnosed T2DM patients were recruited for model development and validation, respectively. Renal impairment was defined as eGFR < 60 mL/min/1.73 m 2 and/or urinary albumin‐to‐creatinine ratio (UACR) ≥ 30 mg/g. Obesity‐ or metabolism‐related indicators were collected. Significantly independent indicators were selected via bidirectional stepwise regression in the modeling patients to develop a comprehensive index termed InMOI. In the validation patients, restricted cubic spline analysis examined the dose‐response relationship between InMOI and renal impairment, whereas ROC curves assessed the screening performance. Results: The triglyceride‐glucose index (TyG) combined with various obesity measures showed significant associations with renal impairment. The InMOI, derived from TyG‐BMI and TyG‐waist to hip ratio (TyG‐WHR), demonstrated a linear dose‐response relationship with the odds ratio for renal impairment. InMOI achieved an AUC of 0.78 for identifying renal impairment. Optimizing the index by replacing WHR with the visceral‐to‐subcutaneous fat area ratio measured by DEXA, the modified InMOI (m‐InMOI) showed a better performance (AUC = 0.81). Conclusion: This study underscores the value of metabolism‐obesity indices in early detection of diabetic renal damage and highlights the pathogenic role of visceral obesity and metabolic dysregulation in diabetic kidney disease. The InMOI provides a practical tool for large‐scale screening and early prevention of diabetic kidney disease.Keywords
Funding Information
- Lishui University (X111001)
This publication has 23 references indexed in Scilit:
- Obesity‐related glomerulopathy: Current approaches and future perspectivesObesity Reviews, 2022
- Body Mass Index and Risk of Diabetic Nephropathy: A Mendelian Randomization StudyThe Journal of Clinical Endocrinology & Metabolism, 2022
- 2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2022Diabetes Care, 2021
- IL-10 Deficiency Aggravates Renal Inflammation, Fibrosis and Functional Failure in High-Fat Dieted Obese MiceTissue Engineering and Regenerative Medicine, 2021
- Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017The Lancet, 2020
- Association of insulin resistance and β-cell dysfunction with incident diabetes among adults in China: a nationwide, population-based, prospective cohort studyThe Lancet Diabetes & Endocrinology, 2020
- Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trialThe Lancet Diabetes & Endocrinology, 2014
- Association of Weight Status With Mortality in Adults With Incident DiabetesJAMA, 2012
- The Product of Triglycerides and Glucose, a Simple Measure of Insulin Sensitivity. Comparison with the Euglycemic-Hyperinsulinemic ClampThe Journal of Clinical Endocrinology & Metabolism, 2010
- Hypertension-Related Renal Injury: A Major Contributor to End-Stage Renal DiseaseAmerican Journal of Kidney Diseases, 1993